MarketMoodz
JPMorgan sees Lilly as GLP-1 DTC winner with rising upside
JPMorgan identifies Eli Lilly as the top winner in the GLP-1 obesity market, powered by LillyDirect’s direct-to-consumer model. The notes project meaningful upside as cash-pay uptake and upcoming payer coverage expand access, with Medicare set to start in April.
Key Takeaways
- Lilly Direct-to-Consumer (LillyDirect) positions Lilly as the best-in-class winner in the GLP-1 obesity market.
- Q4 2025 DTC GLP-1 patients reached roughly 1.5 million per JPMorgan notes.
- US GLP-1 patient pool could grow to about 8 million by 2030 under cash-pay assumptions.
- Medicare coverage for GLP-1s begins in April, with about 4.5 million beneficiaries on GLP-1 therapy projected by 2030.
- Risks include regulatory/pricing dynamics and payer access that could cap upside; Novo Nordisk remains a competitive force.
People Involved
- Chris Schott JPMorgan Analyst
Entities Involved
- Eli Lilly and Company (LLY) Pharmaceutical company developing GLP-1 obesity drugs
- Novo Nordisk A/S Competitor in GLP-1 obesity market
- LillyDirect Lilly's direct-to-consumer platform for GLP-1 therapies
- Medicare U.S. government program covering GLP-1 therapy
MarketMoodz Analysis
For investors, the core implication is potential margin expansion as more patients pay cash or shift to Medicare coverage. JPMorgan’s thesis suggests Lilly could outpace peers if DTC uptake and payer access scale as projected, supporting earnings upside and multiple expansion.
The broader context shows GLP-1 obesity drugs expanding rapidly in the US, aided by consumer uptake and evolving payer dynamics. Novo Nordisk’s next-generation obesity drug reportedly did not match Lilly’s Zepbound in weight loss, underscoring competitive risk and the sensitivity of outcomes to real-world efficacy and pricing.
Policy timing and scope remain the key swing factors. Monitor Medicare rollout, payer coverage decisions, and the potential entry of Lilly’s oral GLP-1 as catalysts or headwinds for adoption.
Source: Original Article
Get AI-Powered Market Insights
Stay ahead of market-moving events with our real-time analysis and stock ratings.
Start Your Free Trial